



## Wave Life Sciences to Webcast Conference Call of Fourth Quarter and Full Year 2022 Financial Results on March 22, 2023

March 2, 2023

CAMBRIDGE, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that management will host a live webcast and conference call at 8:30 a.m. ET on Wednesday, March 22, 2023, to discuss the company's fourth quarter and full year 2022 financial results and provide a business update.

The webcast of the conference call may be accessed by visiting "Investor Events" on the investor relations section of the Wave Life Sciences corporate website: [ir.wavelifesciences.com/events-and-presentations](http://ir.wavelifesciences.com/events-and-presentations).

Analysts planning to participate during the Q&A portion of the live call can join the conference call at the following audio conferencing link: [available here](#). It is recommended that participants register at least 15 minutes in advance of the call. Once registered, participants will receive the dial-in information.

Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.

### About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases. Wave aspires to develop best-in-class medicines across multiple therapeutic modalities using PRISM, the company's proprietary discovery and drug development platform that enables the precise design, optimization, and production of stereopure oligonucleotides. Driven by a resolute sense of urgency, the Wave team is targeting a broad range of genetically defined diseases so that patients and families may realize a brighter future. To find out more, please visit [www.wavelifesciences.com](http://www.wavelifesciences.com) and follow Wave on Twitter @WaveLifeSci.

### Investor Contact:

Kate Rausch  
617-949-4827  
[InvestorRelations@wavelifesci.com](mailto:InvestorRelations@wavelifesci.com)

### Media Contact:

Alicia Suter  
617-949-4817  
[asuter@wavelifesci.com](mailto:asuter@wavelifesci.com)



Source: Wave Life Sciences USA, Inc.